Sunday, April 24, 2022 4:21:14 PM
I'm done posting on this board. But it's been nice communicating with you. I'm vested in all the above so maybe we'll continue on any of the other boards.
Good luck to you.
Recent SLRX News
- Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/22/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:02:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:29:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:25:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:13:07 PM
- Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders • GlobeNewswire Inc. • 01/16/2024 01:00:00 PM
- Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment • GlobeNewswire Inc. • 01/03/2024 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:04:46 PM
- Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program • GlobeNewswire Inc. • 11/07/2023 01:30:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 10/27/2023 07:57:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 09:09:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:14:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:13:50 PM
- Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 08/10/2023 08:05:00 PM
- Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources • GlobeNewswire Inc. • 08/08/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2023 01:22:11 PM
- Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients • GlobeNewswire Inc. • 07/11/2023 12:30:00 PM
- Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress • GlobeNewswire Inc. • 06/12/2023 12:00:00 PM
- Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 05/16/2023 08:05:00 PM
- Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 05/12/2023 12:00:00 PM
- Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 05/11/2023 12:00:00 PM
- FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma • GlobeNewswire Inc. • 05/09/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM